Sweeteners and Sweetness Enhancers: Prolonged Effects on Health, Obesity and Safety (SWEET)
Obesity

About this trial
This is an interventional prevention trial for Obesity
Eligibility Criteria
Inclusion criteria for adults:
- Age: 18-65 years.
- BMI: ≥25.0 kg/m2 (no upper limit). For women: Use of contraceptive methods and not wishing/planning to become pregnant in the 1 year of the intervention study.
- Regular consumption of sugar-containing/sugar-sweetened products.
- Able to participate in CIDs and dietician meetings during normal working hours.
- Motivation and willingness to be randomized to any of the two groups and to do the best to follow the given protocol.
Inclusion criteria for children:
- Age: 6-12 years.
- BMI-for-age: >85th percentile (no upper limit).
- Able to participate in CIDs during normal working hours.
- Motivation and willingness to be randomized to any of the two groups and to do the best to follow the given protocol.
Exclusion criteria for adults:
- Weight change (increase or decrease) >5% during the past 2 months prior to the study.
- Surgical treatment of obesity.
- Blood donation < 3 month prior to study.
- Change in smoking habits during the last month. Smoking is allowed provided subjects have not recently changed habits. However, smoking status is monitored throughout the study and used as a confounding variable.
- Regularly drinking >21 alcoholic units per week (men), or >14 alcoholic units/week (women).
- Intensive physical training (>10 hours of per week).
- Self-reported eating disorders.
- Intolerance and allergies expected to interfere with the study.
- Self-reported drug abuse within the previous 12 months.
- Night- or shift work that ends later than 11 PM.
- For women: Pregnancy, lactation.
- Persons who do not have access to either (mobile) phone or internet (this is necessary when being contacted by the study personnel during the study).
- Insufficient communication with national language.
- Inability, physically or mentally, to comply with the procedures required by the study protocol as evaluated by the daily study manager, site-PI, PI or clinical responsible
- Participant's general condition contraindicates continuing the study as evaluated by the daily study manager, site-PI, PI or clinical responsible.
- Simultaneous participation in other clinical intervention studies.
Medical conditions as known by the persons:
- Diagnosed diabetes mellitus.
- Medical history of CVD (e.g. current angina; myocardial infarction or stroke within the past 6 months; heart failure; symptomatic peripheral vascular disease).
- Systolic blood pressure above 160 mmHg and/or diastolic blood pressure above 100 mmHg (measured at screening) whether on or off treatment for hypertension.
- Significant liver disease, e.g. cirrhosis (fatty liver disease allowed).
- Malignancy which is currently active or in remission for less than five years after last treatment (local basal and squamous cell skin cancer allowed).
- Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption.
- Thyroid diseases, except those on Levothyroxine treatment of hypothyroidism if the person has been on a stable dose for at least 3 months.
- Psychiatric illness (e.g. major depression, bipolar disorders).
Medication:
- Use currently or within the previous 3 months of prescription or over the counter medication that has the potential of affecting body weight incl. food supplements. Except: low dose antidepressants if they, in the judgement of the daily study manager, site-PI, PI or clinical responsible, do not affect weight or participation to the study protocol. Levothyroxine for treatment of hypothyroidism is allowed if the person has been on a stable dose for at least 3 months.
- Cholesterol or blood pressure lowering medication, if the dose has changed during the last 3 months (i.e. the medication is allowed if the participant has been on a stable dose for at least 3 months).
Laboratory screening:
If all of the above criteria are satisfied, the adult participant is eligible for a laboratory screening. A blood sample is collected and immediately analysed for glucose and haemoglobin concentrations (Haemocue).
- Glucose ≥ 7.0 mmol/L.
- Haemoglobin concentration below local laboratory reference values (i.e. anaemia).
- Or any other significant abnormality on these tests which in the investigators opinion may be clinically significant and require further assessment.
After WL period (CID2, Month 2):
Failure to reach at least 5% weight reduction during the WL period (Months 0-2). This leads to exclusion from the WM intervention
Exclusion criteria for children:
- Intensive physical training (>10 hours of per week).
- Self-reported eating disorders.
- Intolerance and allergies expected to interfere with the study.
- Insufficient communication with national language.
- Inability, physically or mentally, to comply with the procedures required by the study protocol as evaluated by the daily study manager, site-PI, PI or clinical responsible.
- Subject's general condition contraindicates continuing the study as evaluated by the daily study manager, principal investigator or clinical responsible.
- Simultaneous participation in other clinical intervention studies.
Medical conditions as known by the child and the representative adult:
- Diagnosed diabetes mellitus.
- Other diseases that may influence the study outcomes as evaluated by the daily study manager, site-PI, PI or clinical responsible.
Medication:
- Use currently or within the previous 3 months of prescription or over the counter medication that has the potential of affecting body weight.
Sites / Locations
- Department of Nutrition, Exercise and Sports
- Harokopio University
- University of Maastricht
- University of Navarra
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Sweeteners and sweetness enhancers (S&SEs)
Sugar group
Healthy diet < 10 energy % (E%) sugar, foods and drinks with S&SEs allowed.
Healthy diet, < 10 E% sugar, foods and drinks with S&SEs not allowed.